View Financial HealthSartorius Stedim Biotech 配当と自社株買い配当金 基準チェック /06Sartorius Stedim Biotech配当を支払う会社であり、現在の利回りは0.41%です。主要情報0.4%配当利回り0.004%バイバック利回り総株主利回り0.4%将来の配当利回り0.8%配当成長10.1%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向25%最近の配当と自社株買いの更新お知らせ • Feb 07+ 1 more updateSartorius Stedim Biotech S.A. Approves Dividend for Fiscal 2025, Payable as from April 2, 2026Sartorius Stedim Biotech S.A. resolved at its meeting, on February 4, 2026, to propose a dividend of 0.69 euros per share for fiscal 2025 to the combined Annual Shareholders’ Meeting on March 24, 2026 – the same amount as in 2024. The total distributed profit would be 67.1 million euros. The dividend will be paid to shareholders as from April 2, 2026.お知らせ • Feb 09Sartorius Stedim Biotech S.A. Propose Dividend for Fiscal 2024, Payable on April 4, 2025Sartorius Stedim Biotech S.A. resolved at its meeting to submit a proposal to the combined Annual Shareholders’ Meeting on March 25, 2025, to pay a dividend of 0.69 euros per share for fiscal 2024, the same amount as for the previous year. The dividend will be paid as from April 4, 2025.すべての更新を表示Recent updatesお知らせ • Feb 07+ 1 more updateSartorius Stedim Biotech S.A. Approves Dividend for Fiscal 2025, Payable as from April 2, 2026Sartorius Stedim Biotech S.A. resolved at its meeting, on February 4, 2026, to propose a dividend of 0.69 euros per share for fiscal 2025 to the combined Annual Shareholders’ Meeting on March 24, 2026 – the same amount as in 2024. The total distributed profit would be 67.1 million euros. The dividend will be paid to shareholders as from April 2, 2026.お知らせ • Dec 20+ 4 more updatesSartorius Stedim Biotech S.A. to Report First Half, 2026 Results on Jul 23, 2026Sartorius Stedim Biotech S.A. announced that they will report first half, 2026 results on Jul 23, 2026お知らせ • Jun 20Sartorius Stedim Biotech Sa Announces Board ChangesIn its meeting, the Board of Directors of Sartorius Stedim Biotech S.A. (SSB) acknowledged the resignation of Dr. Joachim Kreuzburg as member of the Board as of June 30, 2025. As his replacement, the Board co-opted Dr. Michael Grosse, Joachim Kreuzburg´s successor as CEO of Sartorius AG, SSB’s majority shareholder. Michael Grosse was also appointed as the new Chairman of the Board of SSB. Joachim Kreuzburg had served as the Board’s Chairman since June 29, 2007, and had announced his departure in December 2024. Dipl.-Ing. Michael Grosse (58) holds a doctorate in mechanical engineering and has held various management and board positions in the packaging industry for the pharmaceutical and food sector over the past 20 years. He was announced as Sartorius AG CEO in December 2024. From 2020 to 2023, he was Chairman of the Management Board and Chief Executive Officer of Syntegon Technology GmbH, an international market leader in process and packaging solutions based in Germany, which was spun off from the Bosch Group in 2019. Prior to that, Grosse worked for the Swiss company Tetra Pak for many years, where he became a member of the Executive Board in 2006, and where he was responsible for the expansion of the global service business and held various management positions in product development. Before joining Tetra Pak, Grosse worked in the automotive industry at BMW and Ford.お知らせ • Apr 17Sartorius Stedim Biotech S.A. Provides Sales Guidance for Fiscal 2025Based on the first quarter results and the expected continued positive market developments, Sartorius Stedim Biotech S.A. management projects sales revenue growth of around 7% for fiscal 2025, at this point in time with a forecast range of around plus/minus two percentage points due to the continued above-average volatility.お知らせ • Mar 27+ 1 more updateSartorius Stedim Biotech S.A. Elects Cécile Dussart and Christopher Nowers as Board MembersSartorius Stedim Biotech S.A. at the Combined Annual Shareholders Meeting held on March 25, 2025, elected Cécile Dussart and Christopher Nowers as new Board Members. To ensure staggering of office terms, both were appointed for three years. Effective March 25, 2025, the Board of Directors of Sartorius Stedim Biotech S.A. is composed of: Joachim Kreuzburg (Chairman), René Fáber (CEO), Pascale Boissel, Susan Dexter, Cécile Dussart, Romaine Fernandes (Director Representing Employees), Anne-Marie Graffin (Lead Independent Director), Lothar Kappich, and Christopher Nowers.お知らせ • Feb 09Sartorius Stedim Biotech S.A. Propose Dividend for Fiscal 2024, Payable on April 4, 2025Sartorius Stedim Biotech S.A. resolved at its meeting to submit a proposal to the combined Annual Shareholders’ Meeting on March 25, 2025, to pay a dividend of 0.69 euros per share for fiscal 2024, the same amount as for the previous year. The dividend will be paid as from April 4, 2025.お知らせ • Jan 30Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 25, 2025Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 25, 2025.お知らせ • Jan 28+ 1 more updateSartorius Stedim Biotech S.A. to Report First Half, 2025 Results on Jul 22, 2025Sartorius Stedim Biotech S.A. announced that they will report first half, 2025 results on Jul 22, 2025お知らせ • Jan 18Sartorius Stedim Biotech S.A. to Report Q1, 2025 Results on Apr 17, 2025Sartorius Stedim Biotech S.A. announced that they will report Q1, 2025 results on Apr 17, 2025お知らせ • Nov 16Sartorius Stedim Biotech S.A. to Report Fiscal Year 2024 Results on Jan 28, 2025Sartorius Stedim Biotech S.A. announced that they will report fiscal year 2024 results on Jan 28, 2025お知らせ • Feb 08Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion. Security Name: Shares Security Type: Common Stock Transaction Features: Subsequent Direct Listingお知らせ • Feb 07Sartorius Stedim Biotech S.A. has completed a Follow-on Equity Offering in the amount of €1.2 billion.Sartorius Stedim Biotech S.A. has completed a Follow-on Equity Offering in the amount of €1.2 billion. Security Name: Shares Security Type: Common Stock Securities Offered: 5,150,215 Price\Range: €233 Transaction Features: Subsequent Direct Listingお知らせ • Jan 02+ 5 more updatesSartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2024Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2024.お知らせ • Jan 28+ 1 more updateSartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023Sartorius Stedim Biotech S.A. provided earnings guidance for the fiscal year 2023. For the year, the company expects consolidated sales revenue is to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the mid to high single-digit percentage range.お知らせ • Dec 22Sartorius Stedim Biotech S.A. to Report Fiscal Year 2022 Results on Jan 26, 2023Sartorius Stedim Biotech S.A. announced that they will report fiscal year 2022 results on Jan 26, 2023決済の安定と成長配当データの取得安定した配当: SDMH.FはUS市場で注目すべき配当金を支払っていないため、支払いが安定しているかどうかを確認する必要はありません。増加する配当: SDMH.FはUS市場で注目すべき配当金を支払っていないため、支払額が増加しているかどうかを確認する必要はありません。配当利回り対市場Sartorius Stedim Biotech 配当利回り対市場SDMH.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (SDMH.F)0.4%市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Life Sciences)0.7%アナリスト予想 (SDMH.F) (最長3年)0.8%注目すべき配当: SDMH.Fの配当金 ( 0.41% ) はUS市場の配当金支払者の下位 25% ( 1.38% ) と比べると目立ったものではありません。高配当: SDMH.Fの配当金 ( 0.41% ) はUS市場の配当金支払者の上位 25% ( 4.2% ) と比較すると低いです。株主への利益配当収益カバレッジ: SDMH.F US市場において目立った配当金を支払っていません。株主配当金キャッシュフローカバレッジ: SDMH.F US市場において目立った配当金を支払っていません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/24 11:33終値2026/06/24 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sartorius Stedim Biotech S.A. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。25 アナリスト機関Charles PitmanBarclaysNithya BalasubramanianBernsteinDelphine Le LouetBernstein22 その他のアナリストを表示
お知らせ • Feb 07+ 1 more updateSartorius Stedim Biotech S.A. Approves Dividend for Fiscal 2025, Payable as from April 2, 2026Sartorius Stedim Biotech S.A. resolved at its meeting, on February 4, 2026, to propose a dividend of 0.69 euros per share for fiscal 2025 to the combined Annual Shareholders’ Meeting on March 24, 2026 – the same amount as in 2024. The total distributed profit would be 67.1 million euros. The dividend will be paid to shareholders as from April 2, 2026.
お知らせ • Feb 09Sartorius Stedim Biotech S.A. Propose Dividend for Fiscal 2024, Payable on April 4, 2025Sartorius Stedim Biotech S.A. resolved at its meeting to submit a proposal to the combined Annual Shareholders’ Meeting on March 25, 2025, to pay a dividend of 0.69 euros per share for fiscal 2024, the same amount as for the previous year. The dividend will be paid as from April 4, 2025.
お知らせ • Feb 07+ 1 more updateSartorius Stedim Biotech S.A. Approves Dividend for Fiscal 2025, Payable as from April 2, 2026Sartorius Stedim Biotech S.A. resolved at its meeting, on February 4, 2026, to propose a dividend of 0.69 euros per share for fiscal 2025 to the combined Annual Shareholders’ Meeting on March 24, 2026 – the same amount as in 2024. The total distributed profit would be 67.1 million euros. The dividend will be paid to shareholders as from April 2, 2026.
お知らせ • Dec 20+ 4 more updatesSartorius Stedim Biotech S.A. to Report First Half, 2026 Results on Jul 23, 2026Sartorius Stedim Biotech S.A. announced that they will report first half, 2026 results on Jul 23, 2026
お知らせ • Jun 20Sartorius Stedim Biotech Sa Announces Board ChangesIn its meeting, the Board of Directors of Sartorius Stedim Biotech S.A. (SSB) acknowledged the resignation of Dr. Joachim Kreuzburg as member of the Board as of June 30, 2025. As his replacement, the Board co-opted Dr. Michael Grosse, Joachim Kreuzburg´s successor as CEO of Sartorius AG, SSB’s majority shareholder. Michael Grosse was also appointed as the new Chairman of the Board of SSB. Joachim Kreuzburg had served as the Board’s Chairman since June 29, 2007, and had announced his departure in December 2024. Dipl.-Ing. Michael Grosse (58) holds a doctorate in mechanical engineering and has held various management and board positions in the packaging industry for the pharmaceutical and food sector over the past 20 years. He was announced as Sartorius AG CEO in December 2024. From 2020 to 2023, he was Chairman of the Management Board and Chief Executive Officer of Syntegon Technology GmbH, an international market leader in process and packaging solutions based in Germany, which was spun off from the Bosch Group in 2019. Prior to that, Grosse worked for the Swiss company Tetra Pak for many years, where he became a member of the Executive Board in 2006, and where he was responsible for the expansion of the global service business and held various management positions in product development. Before joining Tetra Pak, Grosse worked in the automotive industry at BMW and Ford.
お知らせ • Apr 17Sartorius Stedim Biotech S.A. Provides Sales Guidance for Fiscal 2025Based on the first quarter results and the expected continued positive market developments, Sartorius Stedim Biotech S.A. management projects sales revenue growth of around 7% for fiscal 2025, at this point in time with a forecast range of around plus/minus two percentage points due to the continued above-average volatility.
お知らせ • Mar 27+ 1 more updateSartorius Stedim Biotech S.A. Elects Cécile Dussart and Christopher Nowers as Board MembersSartorius Stedim Biotech S.A. at the Combined Annual Shareholders Meeting held on March 25, 2025, elected Cécile Dussart and Christopher Nowers as new Board Members. To ensure staggering of office terms, both were appointed for three years. Effective March 25, 2025, the Board of Directors of Sartorius Stedim Biotech S.A. is composed of: Joachim Kreuzburg (Chairman), René Fáber (CEO), Pascale Boissel, Susan Dexter, Cécile Dussart, Romaine Fernandes (Director Representing Employees), Anne-Marie Graffin (Lead Independent Director), Lothar Kappich, and Christopher Nowers.
お知らせ • Feb 09Sartorius Stedim Biotech S.A. Propose Dividend for Fiscal 2024, Payable on April 4, 2025Sartorius Stedim Biotech S.A. resolved at its meeting to submit a proposal to the combined Annual Shareholders’ Meeting on March 25, 2025, to pay a dividend of 0.69 euros per share for fiscal 2024, the same amount as for the previous year. The dividend will be paid as from April 4, 2025.
お知らせ • Jan 30Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 25, 2025Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 25, 2025.
お知らせ • Jan 28+ 1 more updateSartorius Stedim Biotech S.A. to Report First Half, 2025 Results on Jul 22, 2025Sartorius Stedim Biotech S.A. announced that they will report first half, 2025 results on Jul 22, 2025
お知らせ • Jan 18Sartorius Stedim Biotech S.A. to Report Q1, 2025 Results on Apr 17, 2025Sartorius Stedim Biotech S.A. announced that they will report Q1, 2025 results on Apr 17, 2025
お知らせ • Nov 16Sartorius Stedim Biotech S.A. to Report Fiscal Year 2024 Results on Jan 28, 2025Sartorius Stedim Biotech S.A. announced that they will report fiscal year 2024 results on Jan 28, 2025
お知らせ • Feb 08Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion. Security Name: Shares Security Type: Common Stock Transaction Features: Subsequent Direct Listing
お知らせ • Feb 07Sartorius Stedim Biotech S.A. has completed a Follow-on Equity Offering in the amount of €1.2 billion.Sartorius Stedim Biotech S.A. has completed a Follow-on Equity Offering in the amount of €1.2 billion. Security Name: Shares Security Type: Common Stock Securities Offered: 5,150,215 Price\Range: €233 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 02+ 5 more updatesSartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2024Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2024.
お知らせ • Jan 28+ 1 more updateSartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023Sartorius Stedim Biotech S.A. provided earnings guidance for the fiscal year 2023. For the year, the company expects consolidated sales revenue is to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the mid to high single-digit percentage range.
お知らせ • Dec 22Sartorius Stedim Biotech S.A. to Report Fiscal Year 2022 Results on Jan 26, 2023Sartorius Stedim Biotech S.A. announced that they will report fiscal year 2022 results on Jan 26, 2023